$8.20
3.30% yesterday
Nasdaq, Apr 29, 10:14 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$8.20
+1.09 15.33% 1M
-6.79 45.30% 6M
-3.46 29.67% YTD
-13.78 62.69% 1Y
-40.83 83.28% 3Y
-6.13 42.78% 5Y
-13.90 62.90% 10Y
Nasdaq, Closing price Tue, Apr 29 2025
-0.28 3.30%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Market capitalization $848.84m
Enterprise Value $457.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.90
P/S ratio (TTM) P/S ratio 14.67
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth 59.55%
Revenue (TTM) Revenue $57.88m
EBIT (operating result TTM) EBIT $-534.26m
Free Cash Flow (TTM) Free Cash Flow $-354.66m
Cash position $601.52m
EPS (TTM) EPS $-5.25
P/E forward negative
P/S forward 17.17
EV/Sales forward 9.25
Short interest 31.30%
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Intellia Therapeutics, Inc. forecast:

21x Buy
75%
6x Hold
21%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
75%
Hold
21%
Sell
4%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
58 58
60% 60%
100%
- Direct Costs 10 10
15% 15%
18%
48 48
74% 74%
82%
- Selling and Administrative Expenses 116 116
7% 7%
200%
- Research and Development Expense 456 456
7% 7%
788%
-524 -524
3% 3%
-905%
- Depreciation and Amortization 10 10
15% 15%
18%
EBIT (Operating Income) EBIT -534 -534
4% 4%
-923%
Net Profit -519 -519
8% 8%
-897%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
PRNewsWire
7 days ago
SAN DIEGO , April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foun...
Neutral
PRNewsWire
16 days ago
LOS ANGELES , April 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Intellia Therapeutics ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before...
Neutral
PRNewsWire
16 days ago
NEW YORK , April 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. So what: If you purchased Intellia securities during the Class Period you may be e...
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today